We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Pulmonary Embolism Thrombolysis a Double-Edged Sword

By HospiMedica International staff writers
Posted on 30 Jun 2014
A new study has found that thrombolytic therapy (TT) nearly halved mortality in patients with pulmonary embolism (PE), but at the cost of a higher risk of major bleeding.

Researchers at St. More...
Luke's-Roosevelt Hospital Center (New York, NY, USA), Thomas Jefferson University Hospital (Philadelphia, PA, USA), and other institutions conducted a meta-analysis of studies to determine mortality benefits and bleeding risks associated with TT compared with anticoagulation in acute PE. In all, 16 eligible trials comprising 2,115 individuals were identified over the past four decades. The primary outcomes were all-cause mortality and major bleeding; secondary outcomes were risk of recurrent embolism and intracranial hemorrhage (ICH).

The results showed that TT was associated with a 47% reduction in mortality, and a 2.7-fold increase in major bleeding compared with standard anticoagulant therapy. Major bleeding was not significantly increased in patients younger than age 65, but a subgroup analysis of patients over the age of 65 revealed a threefold increase in risk of major bleeding. Only one small study evaluated the use of catheter-directed TT, which limited the study’s generalizability beyond patients receiving systemic treatment. The study was published in the June 18, 2014, issue of the Journal of the American Medical Association (JAMA).

“Among patients with pulmonary embolism, including those who were hemodynamically stable with right ventricular dysfunction, thrombolytic therapy was associated with lower rates of all-cause mortality and increased risks of major bleeding and ICH,” concluded lead author Saurav Chatterjee, MD, of St. Luke's-Roosevelt, and colleagues. “However, findings may not apply to patients with pulmonary embolism who are hemodynamically stable without right ventricular dysfunction.”

PE is most often caused by a blood clot migrating to the lungs, with the most common source being a deep vein thrombosis (DVT); less common causes include air bubbles, fat droplets, amniotic fluid, or clumps of parasites or tumor cells. Risk factors include burns, cancer, childbirth, a family history of blood clots, fractures of the hips or thigh bone, heart attack or heart surgery, long-term bed rest, severe injury, stroke, surgery, use of birth control pills or estrogen therapy.

Related Links:

St. Luke's-Roosevelt Hospital Center
Thomas Jefferson University Hospital



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Desk Aneroid Sphyg
Diagnostix 750D+
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.